13 November 2025
13 November 2025
The “plausible mechanism pathway” will allow personalised drugs to reach the market sooner for patients with genetic diseases.
Canada will be the first regulated market to undergo a market influx of semaglutide biosimilars.
The WifOR Institute’s ‘handprint’ quantifies positive socioeconomic impact of pharma products, positing a sustainability metric.
The EU Biotech Act was first spoken about in EC President Ursula von der Leyen's political guidelines for 2025 in July 2024.
Preclinical data with a gene therapy has shown potential to restore cardiac function in a rat model of for heart failure.
Modulight’s CEO said IND-enabling studies will be completed in 2027 for its optogenetic technology.
Merging industry-leading business intelligence & award-winning journalism, this is an unrivalled opportunity for engagement with B2B professionals across a network of 40+ leading media websites.
Steer your business strategy with key data and insights from our latest market research reports and company profiles. Not ready to buy? Start small by downloading a sample report first.
Give your business an edge with our leading industry insights.
